Huge hepatocellular carcinoma greater than 10 cm in diameter worsens prognosis by causing distant recurrence after curative resection
Corresponding Author
Kenji Wakayama MD, PhD
Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
Correspondence to: Kenji Wakayama, MD, PhD, Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, N15-W7, Kita-ku, Sapporo, Hokkaido, 060–8638, Japan. Fax: +81-11-717-7515. E-mail: [email protected]
Search for more papers by this authorToshiya Kamiyama MD, PhD
Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
Search for more papers by this authorHideki Yokoo MD, PhD
Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
Search for more papers by this authorTatsuya Orimo MD, PhD
Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
Search for more papers by this authorShingo Shimada MD, PhD
Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
Search for more papers by this authorTakahiro Einama MD, PhD
Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
Search for more papers by this authorHirofumi Kamachi MD, PhD
Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
Search for more papers by this authorAkinobu Taketomi MD, PhD
Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
Search for more papers by this authorCorresponding Author
Kenji Wakayama MD, PhD
Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
Correspondence to: Kenji Wakayama, MD, PhD, Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, N15-W7, Kita-ku, Sapporo, Hokkaido, 060–8638, Japan. Fax: +81-11-717-7515. E-mail: [email protected]
Search for more papers by this authorToshiya Kamiyama MD, PhD
Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
Search for more papers by this authorHideki Yokoo MD, PhD
Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
Search for more papers by this authorTatsuya Orimo MD, PhD
Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
Search for more papers by this authorShingo Shimada MD, PhD
Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
Search for more papers by this authorTakahiro Einama MD, PhD
Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
Search for more papers by this authorHirofumi Kamachi MD, PhD
Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
Search for more papers by this authorAkinobu Taketomi MD, PhD
Department of Gastroenterological Surgery I, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
Search for more papers by this authorAbstract
Background and Objectives
This study aimed to evaluate the impact of huge (≥10 cm) hepatocellular carcinoma (HCC) to the recurrence pattern and the prognosis after hepatectomy.
Methods
574 patients who underwent hepatectomy by 17 surgeons (Open 536 and Laparoscopic 38) for HCC without major vascular invasion from 1990 to 2013 at single institute were retrospectively analyzed.
Results
Huge tumor, age, HCV, multiple tumors and microscopic portal invasion are independent risk factors for overall survival (OS), and huge tumor, ICGR15 ≥16%, multiple tumors, moderate/poor histology, microscopic portal invasion and a positive pathological margin are risk factors for relapse-free survival (RFS). The 5-year OS and RFS of patients with huge HCC (n = 53) (42.9 and 14.2%) were significantly worse than those of patients with HCC <10 cm (n = 521) (71.3 and 33.1%). Huge tumor is an independent risk factor for initial extra-hepatic recurrence (Hazard ratio 7.86, P < 0.0001). The 5-year OS of patients with initial extra-hepatic recurrence (n = 55) was significantly worse than patients with intra-hepatic recurrence (n = 338) (16.8 vs. 50.5%).
Conclusions
Huge HCC (≥10 cm) is an independent risk factor due to a high risk for initial extra-hepatic recurrence. Future systemic adjuvant therapy is needed for these patients. J. Surg. Oncol. 2017;115:324–329. © 2016 Wiley Periodicals, Inc.
REFERENCES
- 1 Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. Lancet 2012; 379: 1245–1255.
- 2 Mazzaferro V, Regalia E, Doci R, et al.: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693.
- 3 Jang JW, Bae SH, Choi JY, et al.: A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management. Cancer Chemother Pharmacol 2007; 59: 9–15.
- 4 Kim YS, Lim HK, Rhim H, et al.: Ablation of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2014; 28: 897–908.
- 5 Llovet JM, Ricci S, Mazzaferro V, et al.: SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–390.
- 6 Yang LY, Fang F, Ou DP, et al.: Solitary large hepatocellular carcinoma: A specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg 2009; 249: 118–123.
- 7 Zhang H, Yuan SX, Dai SY, et al.: Tumor size does not independently affect long-term survival after curative resection of solitary hepatocellular carcinoma without macroscopic vascular invasion. World J Surg 2014; 38: 947–957.
- 8 Shah SA, Wei AC, Cleary SP, et al.: Prognosis and results after resection of very large (>or=10cm) hepatocellular carcinoma. J Gastrointest Surg 2007; 11: 589–595.
- 9 Ishii T, Hatano E, Yasuchika K, et al.: High risk of lung metastasis after resection of hepatocellular carcinoma more than 7 cm in diameter. Surg Today 2014; 44: 1900–1905.
- 10 Yang J, Li C, Wen TF, et al.: Is hepatectomy for huge hepatocellular carcinoma (≥10 cm in diameter) safe and effective? A single-center experience. Asian Pac J Cancer Prev 2014; 15: 7069–7077.
- 11 Zhang YF, Le Y, Wei W, et al.: Optimal surgical strategy for hepatocellular carcinoma with portal vein tumor thrombus: A propensity score analysis. Oncotarget 2016; 7: 38845–38856.
- 12 Lee JM, Jang BK, Lee YJ, et al.: Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis. Clin Mol Hepatol 2016; 22: 160–167.
- 13 Kokudo T, Hasegawa K, Yamamoto S, et al.: Surgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis. J Hepatol 2014; 61: 583–588.
- 14 Wakayama K, Kamiyama T, Yokoo H, et al.: Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium. World J Surg Oncol 2013; 11: 259–268.
- 15 Guglielmi A, Ruzzenente A, Conci S, et al.: Hepatocellular carcinoma: Surgical perspectives beyond the barcelona clinic liver cancer recommendations. World J Gastroenterol 2014; 20: 7525–7533.
- 16 Kamiyama T, Nakanishi K, Yokoo H, et al.: Perioperative management of hepatic resection toward zero mortality and morbidity: Analysis of 793 consecutive cases in a single institution. J Am Coll Surg 2010; 211: 443–449.
- 17 Liau KH, Ruo L, Shia J, et al.: Outcome of partial hepatectomy for large (>10 cm) hepatocellular carcinoma. Cancer 2005; 104: 1948–1955.
- 18 Régimbeau JM, Farges O, Shen BY, et al.: Is surgery for large hepatocellular carcinoma justified? J Hepatol 1999; 31: 1062–1068.
- 19 Poon RT, Fan ST, Wong J. Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. J Am Coll Surg 2002; 194: 592–602.
- 20 Vauthey JN, Lauwers GY, Esnaola NF, et al.: Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002; 20: 1527–1536.
- 21 Meniconi RL, Komatsu S, Perdigao F, et al.: Recurrent hepatocellular carcinoma: A Western strategy that emphasizes the impact of pathologic profile of the first resection. Surgery 2015; 157: 454–462.
- 22 Koh PS, Chan AC, Cheung TT, et al.: Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: A comparative survival analysis. HPB (Oxford) 2015; 18: 72–78.
- 23 Nakagawa T, Kamiyama T, Nakanishi K, et al.: Pulmonary resection for metastases from hepatocellular carcinoma: Factors influencing prognosis. J Thorac Cardiovasc Surg 2006; 131: 1248–1254.
- 24 Tomimaru Y, Wada H, Eguchi H, et al.: Clinical significance of surgical resection of metastatic lymph nodes from hepatocellular carcinoma. Surg Today 2015; 45: 1112–1120.
- 25 Park YJ, Lim do H, Paik SW, et al.: Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma. J Gastroenterol 2006; 41: 1099–1106.
- 26 Cheng AL, Kang YK, Chen Z, et al.: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25–34.
- 27 Yau T, Chan P, Ng KK, et al.: Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: Presence of lung metastasis predicts poor response. Cancer 2009; 115: 428–436.
- 28 Nakano M, Tanaka M, Kuromatsu R, et al.: Kurume Liver Cancer Study Group of Japan. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: A prospective multicenter cohort study. Cancer Med 2015; 4: 1836–1843.
- 29 Chang YJ, Chung KP, Chang YJ, et al.: Long-term survival of patients undergoing liver resection for very large hepatocellular carcinomas. Br J Surg 2016; 103: 1513–1520.
- 30 Hwang S, Lee YJ, Kim KH, et al.: Long-Term outcome after resection of huge hepatocellular carcinoma ≥10 cm: Single-Institution experience with 471 patients. World J Surg 2015; 39: 2519–2528.
- 31 Zhong JH, Rodríguez AC, Ke Y, et al.: Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. Medicine (Baltimore) 2015; 94: e396.
- 32 Bruix J, Takayama T, Mazzaferro V, et al.: STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015; 16: 1344–1354.
- 33 Mazzaferro V, Regalia E, Doci R, et al.: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693–699.
- 34 He W, Zheng Y, Chen M, et al.: Resection versus ablation for alpha-fetoprotein positive hepatocellular carcinoma within the milan criteria: A propensity score analysis. Liver Int 2016; 36: 1677–1687.
- 35 Hsueh KC, Lee TY, Kor CT, et al.: The role of liver transplantation or resection for patients with early hepatocellular carcinoma. Tumour Biol 2016; 37: 4193–4201.
